Gluten-free Diet in Patients With Primary Sclerosing Cholangitis (PSC)
Launched by UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF · Jul 2, 2019
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • diagnosed PSC-associated colitis without relevant clinical activity after last coloscopy.
- Exclusion Criteria:
- • patients with coeliac disease or wheat allergy
- • patients with active colitis
- • patients already on gluten-free diet
- • liver transplanted patients
- • patients also diagnosed with autoimmune hepatites (PSC-AIH overlap)
- • coloscopy within 2 months before study
- • Endoscopic retrograde cholangiopancreatography (ERCP) within 3 months before study
- • antibiotics within 3 month before study
About Universitätsklinikum Hamburg Eppendorf
Universitätsklinikum Hamburg-Eppendorf (UKE) is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, UKE integrates state-of-the-art facilities with a multidisciplinary approach, fostering collaboration among top-tier researchers, clinicians, and healthcare professionals. The institution is dedicated to improving patient outcomes by conducting rigorous scientific investigations that address critical health challenges, ultimately contributing to the development of novel therapies and enhancing medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamburg, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials